OUR NEW PROFILE IS:   (NASDAQ: ANIX)

ANIX HAS TWO VACCINES AIMED TO PREVENT BREAST CANCER AND OVARIAN CANCER

ANIX HAD $23 MILLION IN CASH AS OF JULY 2023

CHECK OUT THE INVESTOR PRESENTATION HERE

____________________

Hello Everyone,

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors around.

As devastating as cancer is, it’s also a big business. And when cancer and Wall Street collide, it can lead to substantial opportunities to capitalize. It’s no wonder investors are turning their eyes toward healthcare companies specializing in oncology

Precedence Research projects that the global oncology market will increase at a compound annual growth rate of 8.2 percent to reach US$581.25 billion in 2030.

Players in the oncology sector are thriving. Biotech stocks experienced a lift in early December after it was learned that AbbVie will be buying cancer developer ImmunoGen for $10 billion!

Scientific advances are creating new and previously only imaginable ways to treat and prevent diseases.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology.

Pull up ANIX immediately and start your research on the company.

The company’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.

Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.

The Company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple-negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.

These vaccine technologies focus on immunizing against “retired” proteins that are expressed in certain forms of cancer.

THE CAR-T METHOD:

The exciting field known as immunotherapy has enabled the development of drugs that modulate the immune system to battle cancer.We know that our bodies, through the function of our immune systems, are able to “cure” cancer. It is now known that some number of cells in our bodies are becoming cancerous all the time. These transformations are driven by many factors including genetics and environment.

Most of the time without us being consciously aware, these cells are destroyed and cleared by our immune system. As our immune function declines with age, some cells are able to survive and eventually become tumors, either liquid or solid. We also know that the tumors themselves have developed mechanisms to suppress immune cell function. Such is the case with pediatric tumors as well adult cancers.

Considering this understanding, the field of immunotherapy tries to boost the ability of our immune cells to battle the cancer. There are a number of methods that scientists have devised to induce our immune systems to battle cancer. One of those approaches is known a Chimeric Antigen Receptor T-cell technology, better known by the acronym, CAR-T.

CAR-T therapy is a treatment where a patient’s T-cells, a type of immune cell, are removed from the body. These cells are then modified in a laboratory through the advanced techniques of genetic engineering, and increased in number, and then infused back into the patient. In many ways, this is the ultimate personalized medicine. The specific genetic engineering is what makes the patient’s own T-cells even more powerful as a tumor fighter. This genetic engineering causes a special receptor to be present on the surface of the T-cell. This receptor is known as the CAR—the Chimeric Antigen Receptor.

The pharmaceutical industry continues to be a hotbed of innovation and CAR-T cell-based compositions are a key innovation area in immuno-oncology!

CAR-T THERAPY FOR OVARIAN CANCER:

The markets for solid tumors are much larger than the markets for leukemias and lymphomas, especially B-cell cancers. Therefore, ANIXfeels that the scope of opportunities for its CAR- T therapy is very large should the company demonstrate efficacy in solid tumors.

ANIX’S FIRST INDICATION WILL BE OVARIAN CANCER, FOLLOWED BY OTHER TUMOR TYPES.

• ↪Ovarian cancer is the sixth most common cancer in the world, and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches.
• ↪Late-stage diagnosis results in relatively high risks of recurrence and often poor prognosis. While the five-year survival rate for stage 1 ovarian cancer is over 80%, the corresponding survival rate for Stage 4 cancer is 20%. Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.

THE FIRST POTENTIAL ANTI-ANGIOGENIC CAR-T THERAPY:

ANIX has an exclusive worldwide license from The Wistar Institute.

The company believes its CER-T approach will work in solid tumors, especially ovarian cancer, where others have failed.

• ↪FSHR is a unique target
• ↪FSH is a natural ligand (not synthetic)
• ↪The company’s approach may provide anti-angiogenic synergy
• ↪The company’s CAR-T may execute a dual mechanism of action in destroying the tumor

PREVIOUS CHALLENGES:

• ↪The CAR-T cells may not br susceptible to the highly suppressive tumor microenvironment
• ↪As the CAR-T cells are destroying vasculature, they make it leakier, enabling simultaneous, localized delivery of oher agents including chemotherapy
• ↪CAR-T mediated cell death may be more powerful than ther anti-angiogensis drugs

COLLABORATORS INCLUDE:

MOFFITT CANCER CENTER:

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999.

THE WISTAR INSTITUTE CANCER CENTER:

Founded in 1892 as the nation’s first independent biomedical research institute and located on the campus of the University of Pennsylvania, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI’s select network of national cancer research centers, holding an ‘Exceptional’ rating — the highest possible ranking awarded.

CANCER VACCINES:

Vaccines harness the immune system to keep people safe from infectious diseases. Thanks to broad-based vaccination programs, some of the most terrifying diseases in history, small pox and polio among them, have been eliminated from existence.

Unfortunately, there’s been little success in developing a preventative (prophylactic) vaccine against cancer.

Most vaccines attack pathogens, such as viruses and bacteria. The immune system is better able to assail these agents because they come from outside the body. Cancer, however, is a different matter. The disease is caused by aberrant cells that arise out of our resident cells. That can make it difficult for our immune system to find the diseased cells, especially as advancing age weakens our immune system. Once these aberrant cells gain critical mass, they become cancer.

Despite the lack of success with cancer vaccines, recently gained knowledge about the human immune system has led to the development, approval and commercialization of revolutionary immuno-therapy drugs. These drugs do not attack cancer directly, but rather modulate the immune system in ways that enable it to destroy or dramatically impair cancer cells.

Imagine if we could train the immune system to kill cancer cells as they arise before they form into tumors. Perhaps, we could eliminate the onset of cancer. The difficulty has been to identify an agent that allows the immune system to target malignant cells without harming healthy tissue.

• ↪Cleveland Clinic researchers have identified a protein called alpha-lactalbumin that is present in healthy breast tissue only when a woman is lactating and disappears when she stops nursing her child. Alpha-lactalbumin is never present on any other cell in the body. However, it does show up in many types of breast cancer, including an aggressive and deadly form of the disease known as Triple Negative Breast Cancer (TNBC).
• ↪In addition, Cleveland Clinic researchers have identified that the extracellular domain of anti-Mullerian hormone receptor II (AMHR2-ED) is expressed in normal ovaries, and nowhere else in the body, with this expression ceasing after menopause. However, this protein is also expressed in cancerous ovary cells.
• ↪Cleveland Clinic, has received an “Intention to Grant” notice from the European Patent Office (“EPO”) for the patent application titled “Ovarian Cancer Vaccines.”

BY DEVELOPING VACCINES THAT TARGET ALPHA-LACTALBUMIN AND AMHR2-ED, ANIX FEELS THE IMMUNE SYSTEM CAN DESTROY BREAST CANCER CELLS AND OVARIAN CANCER CELLS, RESPECTIVELY, AS THEY ARISE AND ULTIMATELY PREVENT TUMORS FROM FORMING!

Anixa’s ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.

THE MARKET FOR PROPHYLACTIC CANCER VACCINES IS SIZABLE, BIGGER IN FACT THAN THE MARKET FOR ANY TYPE OF CANCER THERAPEUTIC. AFTER ALL, DOCTORS ADMINISTER CANCER DRUGS ONLY AFTER A PATIENT HAS BEEN DIAGNOSED, WHILE A VACCINE CAN BE ADMINISTERED TO A FAR WIDER POPULATION.

BREAST CANCER:

In the U.S., nearly 300,000 women are expected to be diagnosed with breast cancer this year.

OVARIAN CANCER:

Ovarian cancer is the sixth most common cancer in the world, and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches. Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.

PHASE 1 TRIAL FOR BREAST CANCER VACCINE: CONDUCTED BY CLEVELAND CLINIC, FUNDED BY U.S. DEPARTMENT OF DEFENSE (DOD)

AN OPEN-LABEL PHASE 1 DOSE-ESCALATION TRIAL

DESIGN

Participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response

PHASE 1A
(IN PROGRESS)

• ↪18-24 Patients who have been treated for TNBC
• ↪Safety will be monitored
• ↪Immune Response will be monitored
• ↪Maximum Tolerated Dose (“MTD”) determined

PHASE 1B
(ENROLLMENT OPEN)

• ↪Healthy women w/mutations
• ↪Chosen to undergo prophylactic mastectomy
• ↪Vaccinate before surgery and evaluate immune response and resected tissue
• ↪Unique opportunity to garner supplemental data after studying breast tissue to determine if T cells are surveilling the tissue without any visible cancer tumors

PHASE 1C
(ENROLLMENT OPEN)

• ↪Additional cohort combining vaccine with Keytruda
• ↪Patients treated for TNBC
• ↪Combine Keytruda w/ vaccine to evaluate if there is synergy

POSITIVE CLINICAL RESULTS AS OF APRIL 2023:

• ↪Enrollment of women who have had TNBC and have undergone standard of care, but are at risk of recurrence
• ↪42% of TNBC survivors will relapse within 5 years
• ↪MTD reached in Q4 2022 § Data from all vaccinated women tested to date presented at AACR in April 2023
• ↪16 patients dosed through July 2023
• ↪No safety concerns
• ↪Immune responses observed at all dose levels
• ↪All patients had some immune response
• ↪Intensity of responses varied with patients

IN SUMMARY…

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells.The goal to prevent the disease or eradicate it has been monumental in big pharma for decades.

With multiple catalysts over the next 12 months across its clinical pipeline, now is a pivotal time to have Anixa Biosciences, Inc. (NASDAQ: ANIX) on your radar. The company has 2 clinical trials in progress, showing positive results!

ANIX highlights:

• ↪$25M+ in cash as of July 2023
• ↪A low-cost business model
• ↪Developing programs with partners
• ↪Leveraging existing infrastructure of partners
• ↪Maintaining low overhead and cash burn
• ↪Potential to out-license programs to pharma for late stage clinical development and commercialization

NEWS

ANIXA BIOSCIENCES ANNOUNCES EUROPEAN PATENT ON OVARIAN CANCER VACCINE TECHNOLOGY

NOVEMBER 27, 2023

ANIXA BIOSCIENCES TO PRESENT AT THE OVARIAN CANCER RESEARCH ALLIANCE (OCRA) OVARIAN CANCER NATIONAL CONFERENCE

OCTOBER 31, 2023

ANIXA BIOSCIENCES APPOINTS ACCOMPLISHED MEDICAL ONCOLOGIST AND BIOTECHNOLOGY EXECUTIVE, DR. MARK A. GOLDBERG, TO CANCER BUSINESS ADVISORY BOARD

OCTOBER 23, 2023

ANIXA BIOSCIENCES COMPLETES TREATMENT OF FIRST PATIENT COHORT IN OVARIAN CANCER CAR-T CLINICAL TRIAL

OCTOBER 13, 2023

ANIXA BIOSCIENCES ANNOUNCES ISSUANCE OF ADDITIONAL U.S. PATENT FOR OVARIAN CANCER VACCINE TECHNOLOGY

OCTOBER 3, 2023

ANIXA BIOSCIENCES ESTABLISHES CANCER BUSINESS ADVISORY BOARD

SEPTEMBER 19, 2023

ANIXA BIOSCIENCES TO PARTICIPATE IN SEPTEMBER INVESTOR CONFERENCES

AUGUST 31, 2023

ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF THIRD PATIENT IN OVARIAN CANCER CAR-T CLINICAL TRIAL

AUGUST 28, 2023

ANIXA BIOSCIENCES ANNOUNCES INVITED PRESENTATION ON OVARIAN CANCER CAR-T THERAPY AT THE 8TH ANNUAL CAR-TCR SUMMIT

AUGUST 14, 2023

COULD ANIXA BIOSCIENCES (NASDAQ:ANIX) BE DEVELOPING THE VACCINE TO END ONE OF THE DEADLIEST TYPES OF BREAST CANCER?

AUGUST 10, 2023

ANIXA BIOSCIENCES ANNOUNCES OPENING OF ENROLLMENT FOR KEYTRUDA® ARM IN ONGOING BREAST CANCER VACCINE CLINICAL TRIAL

AUGUST 7, 2023

ANIXA BIOSCIENCES ANNOUNCES NOTICE OF ALLOWANCE OF ADDITIONAL PATENT ON OVARIAN CANCER VACCINE TECHNOLOGY

JULY 27, 2023

ANIXA BIOSCIENCES ANNOUNCES ISSUANCE OF CANADIAN PATENT FOR ITS CAR-T CANCER THERAPY TECHNOLOGY

JULY 11, 2023

ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF SECOND PATIENT IN ITS OVARIAN CANCER CAR-T CLINICAL TRIAL

MAY 22, 2023

ANIXA BIOSCIENCES CLARIFIES POSTER PRESENTATION ON COMPANY WEBSITE

APRIL 17, 2023

ANIXA BIOSCIENCES AND CLEVELAND CLINIC PRESENT POSITIVE DATA FOR PHASE 1 STUDY OF BREAST CANCER VACCINE

APRIL 17, 2023

ANIXA BIOSCIENCES ANNOUNCES PRESENTATION ON BREAST CANCER VACCINE TRIAL AT THE 2023 AACR ANNUAL MEETING

MARCH 27, 2023

ANIXA BIOSCIENCES REASSURES SHAREHOLDERS IT HAS NO ACCOUNTS AT SILICON VALLEY BANK

MARCH 13, 2023

ANIXA BIOSCIENCES TO PROVIDE CORPORATE UPDATE AT ITS 2023 ANNUAL MEETING OF STOCKHOLDERS

MARCH 2, 2023

ANIXA BIOSCIENCES ANNOUNCES NOTICE OF ALLOWANCE OF ADDITIONAL KEY PATENT ON BREAST CANCER VACCINE TECHNOLOGY

FEBRUARY 27, 2023

MANAGEMENT TEAM

AMIT KUMAR, PH.D.

Chairman & Chief Executive OfficerDr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

MICHAEL CATELANI

President, COO & CFOMr. Catelani is a seasoned executive with over 30 years of finance and operations management experience. He currently serves as President, Chief Operation Officer & Chief Financial Officer of Anixa Biosciences. Previously, Mike cofounded Tacere Therapeutics, Inc., a privately held biotech company, and served as its Chairman, President & Chief Financial Officer until its sale. Prior to Tacere, Mike served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotech company. Mike was Vice President and Chief Financial Officer at Axon Instruments, a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Axon was a U.S. corporation publicly traded on the Australian Stock Exchange. Previously, he was the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mike has also worked with several early-stage start-ups in a variety of industries, including biotechnology, cleantech  and retail, in both advisory and management roles and has served as a contract CFO for a number of established businesses in the biotech field. Mike began his professional career at Ernst & Young and is a CPA (Inactive). He received his BS degree in business administration, with a concentration in accountancy from Sacramento State University and earned his MBA from the University of California, Davis.

PAMELA D. GARZONE, PH.D.

Chief Development OfficerDr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech. Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. She earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh. She received her Ph.D. in Clinical Science from the University of Pittsburgh.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA, INC FOR A 1 DAY  ANIX AWARENESS CAMPAIGN.  

BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.

‍